The estimated Net Worth of Niall O'donnell is at least $61.6 Million dollars as of 16 February 2023. Mr. donnell owns over 630,400 units of Mirum Pharmaceuticals Inc stock worth over $55,585,443 and over the last 5 years he sold MIRM stock worth over $5,958,000. In addition, he makes $22,942 as Independent Director at Mirum Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. ODonnell MIRM stock SEC Form 4 insiders trading
Niall has made over 4 trades of the Mirum Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 630,400 units of MIRM stock worth $1,998,368 on 16 February 2023.
The largest trade he's ever made was buying 630,400 units of Mirum Pharmaceuticals Inc stock on 16 February 2023 worth over $1,998,368. On average, Niall trades about 148,040 units every 131 days since 2019. As of 16 February 2023 he still owns at least 1,326,305 units of Mirum Pharmaceuticals Inc stock.
You can see the complete history of Mr. donnell stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Niall ODonnell biography
Niall ODonnell serves as Independent Director of the Company. Dr. O’Donnell is currently a managing director at RiverVest Venture Partners, a venture capital firm, a position he has held since April 2014. He joined RiverVest Venture Partners in 2006 where he has focused on biopharmaceutical, diagnostic and medical device opportunities and contributes to the formation, development and business strategies of RiverVest Venture Partners portfolio companies. Dr. O’Donnell currently serves as President and Chief and Executive Officer of Reneo, which he co-founded in December 2017. From 2011 to 2013, he served as acting chief interim medical officer at Lumena, where he led the development and execution of the company’s clinical strategy leading up to its acquisition by Shire plc. Dr. O’Donnell is also a board member of the biopharmaceutical companies Amplyx, Avalyn Pharma, Inc., Curzion and Spruce Biosciences. Dr. O’Donnell received a Ph.D. in biochemistry from the University of Dundee, Scotland, an M.A. in biochemistry from Pembroke College, Oxford and an MBA from the Rady School of Management of the University of California, San Diego.
What is the salary of Niall ODonnell?
As the Independent Director of Mirum Pharmaceuticals Inc, the total compensation of Niall ODonnell at Mirum Pharmaceuticals Inc is $22,942. There are 9 executives at Mirum Pharmaceuticals Inc getting paid more, with Christopher Peetz having the highest compensation of $6,235,180.
How old is Niall ODonnell?
Niall ODonnell is 47, he's been the Independent Director of Mirum Pharmaceuticals Inc since 2018. There are 15 older and 4 younger executives at Mirum Pharmaceuticals Inc. The oldest executive at Mirum Pharmaceuticals Inc is Michael Grey, 67, who is the Chairman of the Board.
What's Niall ODonnell's mailing address?
Niall's mailing address filed with the SEC is C/O RIVERVEST VENTURE PARTNERS, 101 S. HANLEY RD., STE. 1850, ST. LOUIS, MO, 63105.
Insiders trading at Mirum Pharmaceuticals Inc
Over the last 5 years, insiders at Mirum Pharmaceuticals Inc have traded over $10,912,565 worth of Mirum Pharmaceuticals Inc stock and bought 7,735,045 units worth $117,972,829 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Mirum Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $4,538,937. The most recent stock trade was executed by Patrick J Heron on 6 September 2024, trading 230 units of MIRM stock currently worth $9,563.
What does Mirum Pharmaceuticals Inc do?
mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
What does Mirum Pharmaceuticals Inc's logo look like?
Complete history of Mr. donnell stock trades at Mirum Pharmaceuticals Inc and Spruce Biosciences
Mirum Pharmaceuticals Inc executives and stock owners
Mirum Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Christopher Peetz,
President, Chief Executive Officer, Director -
Michael Grey,
Chairman of the Board -
Lara Longpre,
Chief Development Officer -
Pamela Vig,
Chief Scientific Officer -
Christopher Peetz,
Pres, CEO & Director -
Dr. Ian Clements,
Chief Financial Officer -
Peter Radovich M.B.A., Ph.D.,
Chief Operating Officer -
Laurent Fischer,
Independent Director -
Laura Brege,
Independent Director -
Niall ODonnell,
Independent Director -
Edward Mathers,
Independent Director -
Patrick Heron,
Independent Director -
Tiba Aynechi,
Director -
Edwin Tucker,
Chief Medical Officer -
Ian Clements,
Chief Financial Officer -
Vinita P. Kumar,
Sr. vice Pres of Quality -
Lara Longpre MBA, MSC,
Chief Devel. Officer -
Dr. Pamela Vig Ph.D.,
Head of R&D -
Erin Campany,
Sr. VP of HR -
Dr. Edwin Jonathan Tucker M.D.,
Chief Medical Officer -
Paul K. Ross,
Chief Compliance Officer -
Lara Longpre MSC, MBA,
Chief Devel. Officer -
Carol L Brosgart,
Director -
Holdings A/S Novo,
10% owner -
Mohamad Makhzoumi,
10% owner -
Niall O'donnell,
Director -
Peter W. Sonsini,
10% owner -
Anthony A. Jr. Florence,
10% owner -
Ali Behbahani,
10% owner -
Forest Baskett,
10% owner -
Joshua Makower,
10% owner -
David M Mott,
10% owner -
Paul Edward Walker,
10% owner -
Life Sciences Ix, L.P.Fhmls...,
-
Carmen Chang,
10% owner -
Scott D Sandell,
10% owner -
Peter J Barris,
10% owner -
Enterprise Associates 16, L...,
-
James E Deerfield Mgmt Hif,...,
-
Enterprise Associates 16, L...,
10% owner -
William Fairey,
-
Timothy P Walbert,
-
Joanne Quan,
CHIEF MEDICAL OFFICER -
Saira Ramasastry,
-
James E Deerfield Mgmt Hif,...,
-
Lon Cardon,
-
Partners 16, L.P.Nea 16 Gp,...,
-
Jolanda Howe,
SVP, GLOBAL CONTROLLER -
Eric Bjerkholt,
CHIEF FINANCIAL OFFICER -
Peter Radovich,
PRESIDENT AND COO